Aurinia Pharmaceuticals Inc. reported earnings results for the third quarter and nine months ended November 03, 2021. For the third quarter, the company reported revenue was USD 14.67 million compared to USD 0.029 million a year ago. Net loss was USD 50.26 million compared to USD 42.13 million a year ago. Basic loss per share from continuing operations was USD 0.39 compared to USD 0.34 a year ago. Diluted loss per share from continuing operations was USD 0.39 compared to USD 0.34 a year ago. For the nine months, revenue was USD 22.2 million compared to USD 0.088 million a year ago. Net loss was USD 147.64 million compared to USD 94.61 million a year ago. Basic loss per share from continuing operations was USD 1.15 compared to USD 0.82 a year ago. Diluted loss per share from continuing operations was USD 1.15 compared to USD 0.82 a year ago.